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Abstract 
Review the structure, function, and role of CMYC 
gene in tumorigenesis 
Keywords 
MYC; CMYC; MYC signature; transcription factor; 
Burkitt lymphoma; diffuse large B-cell lymphoma; 
follicular lymphoma; mantle cell lymphoma; 
multiple myeloma; lung cancer; breast cancer; colon 
cancer ; prostate cancer 
Identity 
Other names 
CMYC, MYC proto-oncogene, V-MYC avian 
myelocytomatosis viral oncogene homolog, Class E 
Basic Helix-Loop-Helix Protein 39, Transcription 
Factor P64, BHLHe39 
Location 
8q24.21 
MYC (8q24) in normal cells: PAC 944B18 (top) and PAC 968N11 (below) - Courtesy Mariano Rocchi, 
Resources for Molecular Cytogenetics. 
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MYC (MYC proto-oncogene, bHLH 
transcription factor)  Hybridization with Vysis LSI 
MYC break apart and LSY MYC probe (Abbott 
Molecular, US) showing the gene on 8q24.21 - 
Courtesy Adriana Zamecnikova. 
Note 
MYC gene encodes a multifunctional, nuclear 
phosphoprotein that controls a variety of cellular 
functions, including cell cycle, cell growth, 
apoptosis, cellular metabolism and biosynthesis, 
adhesion, and mitochondrial biogenesis. MYC has 
been shown to be an essential global transcription 
factor capable of either promoting or repressing the 
expression of a massive array of genes, accounting 
for >15% of the human genome, commonly referred 
to as the "MYC signature" (Knoepfler 2007). MYC 
is among the most frequently affected gene in human 
cancers, overexpressed in most human cancers and 
contributes to the cause of at least 40% of tumors. 
Dysregulation of MYC expression results through 
various types of genetic alterations leading to a 
constitutive activity of MYC in various cancers 
(Dang et al, 2006). 
DNA/RNA 
Description 
CMYC is composed of three exons spanning over 4 
kb with the second and third  exons encoding most 
MYC protein. These two exons have at least 70% 
sequence homology among species. However, exon1 
is untranslated whose sequence is not as well 
conserved through evolution. The exon1 has been 
postulated to play a role in translational control and 
mRNA stability.  There are four MYC 
transcriptional promoters. In normal cells, promoter 
P2 contributes to approximately 75% of total MYC 
transcripts while P1 accounts for most the remaining 
25% transcripts (Dang CV 2012). 
Transcription 
MYC mRNA contains an IRES (internal ribosome 
entry site) that allows the RNA to be translated into 
protein when 5' cap-dependent translation is 
inhibited, such as during viral infection. 
Protein 
Description 
439 amino acids and 48 kDa in the p64; 454 amino 
acids in the p67 (15 additional amino acids in N-
term; contains from N-term to C-term: a 
transactivation domain, an acidic domain, a nuclear 
localization signal, a basic domain, an helix-loop-
helix motif, and a leucin zipper; DNA binding 
protein. 
Expression 
Expressed in almost all proliferating cells in 
embryonic and adult tissues; in adult tissues, 
expression correlates with cell proliferation; 
abnormally high expression is found in a wide 
variety of human cancers. 
Localisation 
located predominantly in the nucleus.  
 
The myc protein contains an unstructured N-terminal 
transcriptional regulatory domain followed by a 
nuclear localization signal and a C-terminal region 
with a basic DNA-binding domain tied to a helix-
loop-helix-leucine zipper (bHLHZip) dimerization 
motif. The bHLHzip motif of MYC dimerizes with 
the MAX, which is a prerequisite for specific 
binding to DNA at E-box sequences (5'-
CA(C/T)G(T/C)G-3') (Dang 2012). Upon DNA 
binding the MYC/MAX heterodimer recruits co-
factors, which mediate multiple effects of MYC on 
gene expression in a context-dependent manner. 
This dimerization process is essential for induction 
of cell cycle progression, apoptosis, and 
transformation suggesting that MYC exerts its 
oncogenic effects by transactivation of target genes 
via E-boxes (Amati B, Land H, 1994; Grandori C et 
al 2000). The coding exons of MYC encode for the 
N-terminal region which has a transcriptional 
regulatory domain, a region that contains conserved 
MYC Boxes I and II, followed by MYC Box III and 
IV, and a nuclear targeting sequence. The N-terminal 
region will bind with co-activator complexes, 
making MYC acts as the transcription or repression 
factor (Cowling et al 2006).  
 
In normal cells, MYC is tightly regulated by mitotic 
and developmental signals, and in turn, it regulates 
the expression of downstream target genes. Both 
MYC mRNA and protein have very short half-lives 
in normal cells (20-30 minutes each). Without 
appropriate positive regulatory signals, MYC protein 
levels are low and insufficient to promote cellular 
proliferation. In addition, MYC protein is rapidly 
degraded by the ubiquitin-linked proteasome 
machinery. The short-life and instability of MYC 
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protein and mRNA together would seem to be an 
effective safeguard mechanism of MYC regulation 
(Herrick and Ross et al, 1994). However, these 
controls are lost in cancer cells, resulting in 
aberrantly high levels of MYC protein.  In its 
physiological role, MYC is broadly expressed during 
embryogenesis and in tissue with high proliferative 
capacity such as skin epidermis and gut. Its 
expression strongly correlates with cell proliferation. 
Function 
MYC functions as a transcriptional regulator, 
capable to induce or repress the expression of a large 
number of genes, which are thought to mediate its 
biological functions (Adhikary and Eilers 2005). 
MYC protein cannot form homodimers, but it binds 
to MAX that is an obligate heterodimeric partner for 
MYC in mediating its functions. The MYC-MAX 
complex is a potent activator of transcription for a 
critical set of cellular target genes.  Initially, two 
additional partners for Max had been identified, 
MXI1 and MXD1 (Mad1). Two more Max-
interacting proteins, MXD3 (Mad3) and MXD4 
(Mad4), which behave similarly to MXD1 have been 
reported. The transcription activation is mediated 
exclusively by MYC-MAX complexes, whereas 
MAX-MXD1 and MAX-MXI1 complexes mediate 
transcription repression through identical binding 
sites. Max expression is not highly regulated and its 
protein is very stable; in contrast, MXD1 protein 
appears to have a short half-life and to be highly 
regulated (Amati and Land, 1994). MXI1 protein is 
also regulated. MYC-MAX heterodimers activate 
transcription through interactions with 
transcriptional coactivators ( TRRAP, ACTL6A 
(BAF53)) and their associated histone 
acetyltransferases and/or ATPase/helicases, 
resulting in transition from the G0/1 phase to the S 
phase (Nilsson and Cleveland, 2003). Several studies 
have established that MAX is essential for MYC-
mediated gene transactivation, transformation, cell 
cycle progression and apoptosis. On the other hand, 
overexpression of MXI1 and MXD1 can antagonize 
MYC activity in cellular transformation assays and 
proliferation and can diminish the malignant 
phenotype of tumor cells. MXD1 can also inhibit 
apoptosis and reverse the differentiation blocking 
effect of MYC in leukemia cells. (Dang 2012). These 
findings are consistent with the concept that MXD1 
and MXI1 suppress MYC function. In addition to 
interacting with proteins involved in transcription 
regulation, MYC also interacts with enzymes 
controlling histone methylation.  
 
 Target Genes Thousands of MYC target genes 
have been identified by following mRNA levels in 
experimentally controlled activation of the MYC 
gene (Menssen and Hermeking 2002). In general, 
genes targeted by MYC include mediators of 
metabolism, biosynthesis, and cell cycle 
progression, such that aberrant MYC expression is 
associated with uncontrolled cell growth, division, 
and metastasis, whereas loss or inhibition of MYC 
expression hinders growth, promotes differentiation, 
and sensitizes cells to DNA damage (Miller 2012; 
Hsieh 2015). Different target genes are regulated 
under specific conditions for specific cell types. 
Some of the most biologically important targets are 
CCND2 (cyclin D2), and cyclin-dependent kinases 
(CDKs), resulting in accelerated cell cycling; down-
regulation of PTEN (phosphatase and tensin 
homolog deleted on chromosome ten) with 
consequent up-regulation of the phosphoinositide 3-
kinase/protein kinase B/mammalian target of 
rapamycin (PI3K/AKT/ MTOR) pathway; and 
stabilization of  the proapoptotic protein and tumor 
suppressor TP53, (Hoffman and Liebermann 2008; 
Dang 2012) which can bypass the apoptotic BCL2 
program. MYC, on the other hand, activates many 
ribosomal protein genes including RPL23, which 
binds to and retains NPM1 in the nucleolus, thereby 
inhibiting PIAS2 (Miz-1) activity (Wanzel, 2008). 
MYC itself is modulated by NPM1, which acts as a 
positive MYC coactivator (Schneider A 1997; 
Grandori C et al., 2005; Li Z, et al 2008).  
 
MYC-targeted gene network also contains non-
protein coding targets; among those are microRNAs 
(miRNAs). The miRNAs are 18- 22 nucleotides non-
coding RNAs that negatively regulate gene 
expression at the post-transcriptional level via 
binding to 3'-UTRs of target mRNAs and mediate 
translational repression or mRNA degradation. 
Some miRNA function as an oncogene while others 
behave as tumor suppressor gene, in a cell-typed 
manner. Growing evidences have suggested that 
MYC regulates the expression of a number of 
miRNAs, resulting in widespread repression of 
miRNA and, at the same time, MYC being subjected 
to regulation by miRNAs, leading to sustained MYC 
activity and the corresponding MYC downstream 
pathways (Chang et al, 2008). Thus, these combined 
effects of MYC overexpression and downregulation 
of miRNAs play a central regulatory role in the MYC 
oncogenic pathways. For example, MYC 
upregulates expression of miR-17-92 clusters a set of 
oncogenic miRNAs, which contains six mature 
miRNAs. Recently, miR-19 was identified as the key 
oncogenic component of this cluster (Tao et al 2014; 
Koh 2016). Overexpression of miR-17-92 is 
observed in a large fraction of human cancers, 
including carcinomas of the breast, lung, and colon; 
medulloblastomas; neuroblastomas and B-cell 
lymphoma. The miR17-92 is commonly amplified at 
13q31 in several subtypes of aggressive lymphomas.  
Its oncogenic function is reflected by down-
regulation of PTEN, TP53 and E2F1, causing the 
activation of the PI3K/AKT pathway and inhibiting 
cellular apoptosis. The functional interaction 
between miR-17`92 and MYC is further emphasized 
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by the finding that MYC is a potent transcriptional 
activator of miR-17-92 (O'Donnell et al. 2005), thus 
suggesting that miR-17-92 may contribute to the 
oncogenic properties of MYC.   Another MYC-
induced miRNA, MIR22, was recently shown to act 
as a potent proto-oncogenic miRNA by genome-
wide deregulation of the epigenetic state through 
inhibition of methylcytosine dioxygenase TET 
proteins. In addition, MIR22 was characterized as a 
key regulator of self-renewal in the hematopoietic 
system.  MYC also represses several miRNAs with 
tumor suppressor function such as MIR15A/ MIR16-
1 and miR-34 that regulate apoptosis by targeting 
BCL2 and TP53 respectively.  Likewise MYC is 
negatively regulated by several miRNAs such as 
miR-34 and MIR494. The auto functional interaction 
between MYC and miRNAs target genes maintains 
persistent expression of MYC, thus promoting the 
malignant phenotype (Tao et al 2014; Jackstadt 
2015).  
 
Furthermore, over expression of MYC can induce 
apoptosis. The apoptosis triggered or sensitized by 
MYC can be either TP53-dependent or TP53 
independent, determined by the cell type and 
apoptotic trigger. The mechanisms of MYC-
mediated apoptosis may involve several pathways. 
Overexpression of MYC increases DNA replication 
and possibly results in DNA damage that, in turn, 
triggers a TP53-mediated response leading to 
apoptosis, in some cell types (Hoffman and 
Libermann, 2008). As well, MYC expression seems 
to downregulate antiapoptotic proteins such as BCL2 
or BCL2L1 (Bcl-XL) and upregulate pro-apoptotic 
elements such as BCL2L11 (BIM).  
 
MYC also plays an important role in mitochondrial 
biogenesis. Large scale studies of gene expression in 
rat and human systems first suggested that MYC 
overexpression can induce nuclear encoded 
mitochondrial genes. In addition, MYC has been 
shown to bind to the promoters of genes encoding 
proteins involved in mitochondrial function. Using 
an inducible MYC-dependent human B cell model of 
cell proliferation it was shown that mitochondrial 
biogenesis is completely dependent on MYC 
expression. Moreover, the genes involved with 
mitochondrial biogenesis are among the MYC target 
genes most highly induced (Gao et al 2009). 
Implicated in 
Top note 
 MYC Deregulation  
 
The expression of MYC is deregulated in cancer by 
several different mechanisms, including 
chromosomal translocations, amplifications, point 
mutations, epigenetic reprogramming, enhanced 
translation and increased protein stability.  In most 
cases these alterations lead to a constitutive 
expression of intact MYC protein, which is normally 
only expressed during certain phases of the cell 
cycle.  In Burkitt lymphoma (BL), the MYC 
oncogene is activated through a reciprocal t(8;14) or 
its variant which juxtaposes MYC/8q24 to enhancer 
of the immunoglobulin (Ig) heavy Chain (IGH)  
locus on chromosome 14q32 or the kappa or lambda 
light chain locus on chromosome 2 or 22. There are 
three main translocation breakpoints in MYC; class 
I breakpoints are within the exon 1 and first intron of 
MYC; class II breakpoints are located at the 5' end 
of the MYC, and usually within a few kilobases of 
exon 1; and the class III breakpoints are distant from 
MYC itself, and can be more than 100 kb away. 
Endemic BL typically shows class II translocation 
breakpoints in MYC while the sporadic BL often 
exhibits class I breakpoints of MYC. The t(8;14) or 
its variant  is considered as an initiative event in BL. 
The MYC/8q24 translocations may also occur as 
secondary events in non-BL lymphomas such as 
diffuse large B-cell lymphoma, follicular lymphoma, 
mantle cell lymphoma, and multiple myeloma (Cai 
et al, 2015; Nguyen L, et al 2017). Secondary MYC 
translocation is associated with a complex karyotype 
and most often confer aggressive clinical behavior 
and poor outcome. Recently, B-cell large cell 
lymphoma with MYC and BCL2 or/and BCL6 
rearrangements so called double hit or triple hit 
lymphoma are recognized by the 2016 revision of 
WHO as a subset of a very aggressive lymphoma 
(Petrich 2014). > 
 
Amplification of MYC gene has been shown in both 
hematopoietic and non-hematopoietic tumors, 
including lung, breast, colon, and prostate cancers. 
Insertional mutagenesis is seen in retrovirus-induced 
tumors, such as avian leucosis virus (ALV)-induced 
hematopoietic tumors, in which the proviral 
enhancer is integrated upstream of the MYC gene 
and leads to its overexpression. MYC 
overexpression may also occur because of post-
translational modifications. MYC protein 
overexpression as a result of point mutations in N-
terminal domain is also frequent. The most 
recurrently mutated residue is Thr-58, found in 
lymphoma. Normally, the phosphorylation of Thr-58 
can control MYC degradation and mutation causing 
increase of MYC protein half-life in lymphoma (Cai 
et al 2017). Detection of MYC rearrangement is 
important in the diagnosis of BL and as a prognostic 
marker in other aggressive B-cell lymphomas. There 
are several techniques to detect MYC deregulation 
including conventional cytogenetics, fluorescence in 
situ hybridization (FISH), and 
immunohistochemistry. In clinical laboratory, FISH 
is being most frequently used approach (Figure 2) > 
 
 MYC as therapeutic target  
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MYC is documented to be involved broadly in many 
cancers, in which its expression is estimated to be 
elevated or deregulated in up to 70% of human 
cancers. Overexpression of MYC protein is not only 
to drive tumor initiation and progression, but is also 
essential for tumor maintenance. Furthermore, 
growth arrest, apoptosis and differentiation occur 
upon reduction in MYC levels. These features make 
MYC molecule a highly attractive target for cancer 
therapy. However, the lack of deep pocket in the 
structure of MYC protein makes the traditionally 
small molecule inhibitors are not feasible.  For this 
reason, other alternative strategies are proposed. One 
approach suggests that the disruption of the 
MYC/MAX binding site can be a strategy for the 
inactivation of MYC function in neoplastic cells. 
Such an approach was already applied and different 
small molecule inhibitors that can specifically target 
MYC were already successfully produced. Other 
approach is based on the inhibition of MYC/MAX 
dimers binding to E-boxes in the promoters of 
different MYC target genes. Other groups have 
focused on transcriptional inhibition of the MYC 
gene. Preliminary evidence from experiments using 
MYC antisense oligonucleotides has been 
encouraging, but has not translated into effective 
clinical treatments ( Koh  2016). 
 
FISH using MYC/IGH/CEP8 triple color dual fusion 
DNA probe set, showing dual fusion pattern, 
consistent with t(8;14)(q24;q32) [left] in a case with 
Burkitt lymphoma; MYC amplification in acute 
myeloid leukemia [right] - Anwar N. Mohamed. 
Note 
MYC gene encodes a multifunctional, nuclear 
phosphoprotein that controls a variety of cellular 
functions, including cell cycle, cell growth, 
apoptosis, cellular metabolism and biosynthesis, 
adhesion, and mitochondrial biogenesis. MYC has 
been shown to be an essential global transcription 
factor capable of either promoting or repressing the 
expression of a massive array of genes, accounting 
for >15% of the human genome, commonly referred 
to as the "MYC signature" (Knoepfler 2007). MYC 
is among the most frequently affected gene in human 
cancers, overexpressed in most human cancers and 
contributes to the cause of at least 40% of tumors. 
Dysregulation of MYC expression results through 
various types of genetic alterations leading to a 
constitutive activity of MYC in various cancers 
(Dang et al, 2006). 
Breakpoints 
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